 SON-1410 IL18-FHAB-IL12, a bispecific combination of Interleukins 18 and 12, was selected based on data generated in a mouse melanoma study comparing three bispecific constructs Selection of the asset was performed with input from Sonnets Scientific Advisory Board An IND submission for SON-1410 is anticipated during the second half of 2022 PRINCETON, NJ ACCESSWIRE August 30, 2021 Sonnet BioTherapeutics Holdings, Inc., NASDAQ:SONN a biopharmaceutical company developing innovative targeted biologic drugs, announced today that it has selected a novel development candidate after completing comparative studies in a mouse melanoma model. The candidate represents Sonnets second bispecific compound integrating Interleukin 12 IL-12 with the companys Fully Human Albumin Binding FHAB platform. 